Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Universal Health International Group Holding (HKSE:02211) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Universal Health International Group Holding EBITDA Margin % Related Terms
Universal Health International Group Holding EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Universal Health International Group Holding EBITDA Margin % Chart
Universal Health International Group Holding Annual Data
Universal Health International Group Holding EBITDA Margin % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Universal Health International Group Holding's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Universal Health International Group Holding EBITDA Margin % vs Healthcare Providers & Services Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Universal Health International Group Holding (HKSE:02211) has a EBITDA Margin % of 0.78% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Universal Health International Group Holding and its competitors. According to the industry distribution chart, Universal Health International Group Holding ranks #528 out of 672 companies in the Healthcare Providers & Services industry, placing it in the top 78.6%.
Is Universal Health International Group Holding's EBITDA Margin % too high?
Universal Health International Group Holding's current EBITDA Margin % is 0.78%. The Healthcare Providers & Services industry median EBITDA Margin % is 10.18. Universal Health International Group Holding's value of 0.78% is 92.3% below this industry median. Based on the distribution chart, Universal Health International Group Holding ranks #528 out of 672 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Universal Health International Group Holding has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Universal Health International Group Holding's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Universal Health International Group Holding ranks #528 out of 672 companies for EBITDA Margin %. This places Universal Health International Group Holding in the lower half of its industry. The industry median EBITDA Margin % is 10.18. Universal Health International Group Holding's value of 0.78% is 92.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.18, based on 672 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Universal Health International Group Holding's current EBITDA Margin % of 0.78% is 92.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Universal Health International Group Holding and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universal Health International Group Holding's current EBITDA Margin % is 0.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Health International Group Holding stock overvalued right now?
Based on GuruFocus' analysis, Universal Health International Group Holding (HKSE:02211) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.66 — trading 125.9% above its estimated fair value. The current EBITDA Margin % is 0.78% and 92.3% below the Healthcare Providers & Services industry median of 10.18. Universal Health International Group Holding's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Universal Health International Group Holding (HKSE:02211), the current EBITDA Margin % is 0.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Universal Health International Group Holding (HKSE:02211) Overvalued in 2026?
Based on GuruFocus' analysis, Universal Health International Group Holding stock appears to be overvalued.
The current stock price of HK$0.66 is trading 125.9% above its estimated GF Value™ of HK$0.29.
GuruFocus considers Universal Health International Group Holding to be Significantly Overvalued.
Key valuation signals for HKSE:02211:
EBITDA Margin %: 0.78%
GF Value™: HK$0.29 vs. price of HK$0.66 (125.9% above fair value)
Industry Position: 92.3% below the Healthcare Providers & Services median (#528 of 672)
No single metric tells the full story. See the HKSE:02211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Universal Health International Group Holding Ltd distributes and retails pharmaceutical products in Northeast China. The company operates its business through two segments: pharmaceutical retail and Distribution, (including import and export trade) include prescribed drugs, non-prescribed drugs (Chinese patent medicines, chemical preparations, antibiotics and biochemical drugs), traditional Chinese medicine decoction pieces, biological products, protein assimilation preparations, peptide hormones, blood products, disinfection products, medical equipment, etc. and majority of revnue comes from Distribution segment.
37GF Score
Get the complete analysis for HKSE:02211
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02211 has been successfully added to your 
